featured
ESMO 2018: Abiraterone in High and Low Risk, Hormone Sensitive Metastatic Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: